Cellino and Polyphron Teaming Up to Scale Personalized Tissue Manufacturing Derived from iPSCs
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
Key findings
- Cellino and Polyphron have partnered to build an end-to-end manufacturing workflow for personalized tissues, hoping to move regenerative medicine beyond custom, small-batch workflows to scaled manufacturing
- Cellino will supply patient-derived induced pluripotent stem cells (iPSCs), while Polyphron will engineer those cells into functional tissues.
Cellino announced a strategic collaboration with Polyphron to scale manufacturing for regenerative medicine. The companies say the goal is to connect Cellino’s iPSC production with Polyphron’s tissue engineering platform to support personalized tissue replacement.
The bottleneck
Many chronic and age-related diseases involve tissue failure. Cells lose function, structures degrade, and organs stop working. While drugs can often alter biological signaling, reliably rebuilding physical tissue remains difficult, and the limiting factor isn’t just biology, but also the ability to manufacture living cells and tissues with consistent quality at a real-world scale.
What Polyphron is building
Polyphron describes its platform as “The Autonomous Tissue Foundry” designed to make tissue formation more reproducible. It uses AI and automation to scale up biomanufacturing, featuring:
- Closed-loop optimization (a feedback-driven process that iteratively adjusts conditions to reach a target outcome)
- Non-destructive phenotyping (measuring tissue characteristics without destroying the sample)
The stated aim is to converge on “native-like” tissue structure across contexts, while moving away from bespoke, lab-specific protocols. You can read more info on the foundry here.
What Cellino is contributing
Cellino produces induced pluripotent stem cells (iPSCs), reprogrammed cells that can be differentiated into many cell types. Its platform combines lasers, image-based AI, and a closed cassette system to manufacture patient-derived cells with precision and consistency.
How the joint workflow is expected to work
Under the collaboration, Cellino will produce iPSCs at scale. Polyphron will then use those iPSCs as inputs to engineer functional tissues. The companies describe this as an effort to build end-to-end capabilities that could support personalized tissue replacement.
“Regenerative medicine is proving it can reverse late-stage disease in Parkinson’s patients, heart failure, and spinal injury. The next challenge is manufacturing: producing patient-derived cells with the precision and scale required for routine clinical use. That’s what we’ve built Cellino to do, and why working with partners like Polyphron matters so much,” said Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino.
“The era of artisanal tissue engineering is over. To make regenerative medicine real for millions of patients, tissue must be treated as a manufactured product with defined tolerances, not a bespoke laboratory experiment. Cellino delivers precise, patient-derived cellular inputs, and Polyphron provides the systems that organize them into reproducible tissue. Together, we are building the industrial infrastructure required to make human tissue specifiable, reproducible, and scalable,” said Matthew Osman, CEO and Co-Founder of Polyphron.
More information: cellinobio.com. and polyphron.com.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
